[Skip to Content]
[Skip to Content Landing]
Article
December 19, 1990

Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens

Author Affiliations

From the Cardiovascular Research Institute (Drs Kane, Malloy, Ports, Phillips, and Havel and Mr Diehl) and the Department of Medicine (Drs Kane, Malloy, Ports, and Havel), University of California, San Francisco.

From the Cardiovascular Research Institute (Drs Kane, Malloy, Ports, Phillips, and Havel and Mr Diehl) and the Department of Medicine (Drs Kane, Malloy, Ports, and Havel), University of California, San Francisco.

JAMA. 1990;264(23):3007-3012. doi:10.1001/jama.1990.03450230043027
Abstract

We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were measured before and after a 26-month interval by computer-based quantitative angiography. The primary outcome variable was within-patient mean change in percent area stenosis. Mean low-density lipoprotein cholesterol levels decreased from 7.32 ±1.5 to 4.45 ±1.6 mmol/L. The mean change in percent area stenosis among controls was + 0.80, indicating progression, while the mean change for the treatment group was -1.53, indicating regression (P =.039 by two-tailed t test for the difference between groups). Regression among women, analyzed separately, was also significant. The change in percent area stenosis was correlated with low-density lipoprotein levels on trial. We conclude that reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia. The anticipation of benefit from treatment applies to women and men alike.

(JAMA. 1990;264:3007-3012)

×